MNTA: you also assume that Drugstore.com is applying linear discounts to their sales. The discounts, therefore, are not entirely indictative as to what MNTA is offering vendors. (Maybe Drugstore is discounting the generic more than the branded, in-house, due to greater mark-up on the branded.)
Some patients and docs will be very slow to convert to generic…
Patients and prescribing physicians are not the ones who decide whether one gets the generic—that’s the whole point of having a substitutable generic product.
If this is true, then this IMO will be the biggest hurdle for MNTA <<<<Most sales are in hospitals, so how long has S/A tied up the deals? >>>> Sales in hospitals are controlled by the P&T committees and MNTA's drug will have to be reviewed in each case. If you want to know how difficult a process that is, how entrenched a suppler (even of an inferior drug) can be, and finally, how quickly a current supplier can discount then look at the story of ZGEN and KG's thrombin.
Market Data 
Markets 
AI
